Latest Report Available at Analytical Research Cognizance Menopausal Disorders Drug Market provides pin-point analysis for changing competitive dynamics and a forward looking perspective on different factors driving or restraining industry growth.
This report provides an overview of the pipeline landscape for menopausal disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for postmenopausal osteoporosis, vaginal atrophy and vasomotor symptoms of menopause, and features dormant and discontinued products.
Postmenopausal osteoporosis is the most common form of osteoporosis. It affects many women after menopause. Symptoms include back pain, loss of height, or spinal deformities such as stooped posture. Risk factors include age, gender, family history, bone structure and body weight. There are 20 products in development for this indication.
Access The Complet report @ http://www.arcognizance.com/report/menopausal-disorders-drug-development-pipeline-review-2018
Vaginal atrophy is thinning, drying and inflammation of the vaginal walls due to the body having less estrogen. Signs and symptoms include vaginal dryness, vaginal discharge, genital itching, burning with urination, and urgency with urination, urinary tract infections and urinary incontinence.
Risk factor includes smoking. Smoking impairs blood circulation, depriving the vagina and other tissues of oxygen. Tissue thinning occurs where blood flow is decreased or restricted. There are five products in development for this indication.
Vasomotor symptoms of menopause include hot flashes or night sweats that result from sudden opening of the blood vessels close to the skin, usually due to hormonal fluctuations in menopause and perimenopause. These symptoms are caused due to some medications, estrogen withdrawal, thyroid disease, diabetes, hyperhidrosis, anxiety and panic disorders, obesity, hormonally active tumors, chronic infections and neurological disorders. There are 12 products in development for this indication.
Molecular targets acted on by products in development for menopausal disorders include tumor necrosis factor ligand superfamily member 11, parathyroid hormone receptor and progesterone receptor. Companies operating in this pipeline space include Amgen, TherapeuticsMD and Ipsen.
Request for sample copy of report @ http://www.arcognizance.com/enquiry-sample/74587
– Which companies are the most active within each pipeline?
– Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
– To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
– What are the most important R&D milestones and data publications to have happened in this disease area?
Check Discount Offer Before Buying This Report @ http://www.arcognizance.com/discount/74587
Reasons to buy
– Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
– Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
– Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
– Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Enteris BioPharma Inc
GL Pharm Tech Corp
Intas Pharmaceuticals Ltd
Ligand Pharmaceuticals Inc
Luye Pharma Group Ltd
Mithra Pharmaceuticals SA
Paras Biopharmaceuticals Finland Oy
Pherin Pharmaceuticals Inc
Uni-Bio Science Group Ltd
Some Points Of Table Of Content:
1 Table of Contents
2 Introduction 7
3 Therapeutics Development 8
4 Therapeutics Assessment 18
5 Companies Involved in Therapeutics Development 35
6 Dormant Projects 46
7 Discontinued Products 49
8 Product Development Milestones 50
9 Appendix 83
List of tables
1.1 List of Tables
Table 1: Number of Products under Development for Post Menopausal Osteoporosis 8
Table 2: Number of Products under Development by Companies, Post Menopausal Osteoporosis 9
Table 3: Products under Development by Companies, Post Menopausal Osteoporosis 10
Table 4: Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis) 12
Table 5: Number of Products under Development by Companies, Vaginal Atrophy (Atrophic Vaginitis) 13
Table 6: Products under Development by Companies, Vaginal Atrophy (Atrophic Vaginitis) 14
Table 7: Number of Products under Development for Vasomotor Symptoms of Menopause (Hot Flashes) 15
Table 8: Number of Products under Development by Companies, Vasomotor Symptoms of Menopause (Hot Flashes) 16
Table 9: Products under Development by Companies, Vasomotor Symptoms of Menopause (Hot Flashes) 17
Table 10: Number of Products by Stage and Target, Post Menopausal Osteoporosis 19
http://arcognizance.com is an initiation in this new era of “analysis @ thought.” We are on a mission to replace the conventional research programs and give way to the latest methods and information for the organizations. We have created this hub of analytical research papers where you can get an access to the latest and the best research papers coming out from some reliable and budding research houses. After the advent of “new analytics” based on the data collection facilities of big data, the face of “business research facilities” has changed drastically . With ARC our experts have created a bookshelf where you can check out the research reports that are an outcome of the progression of knowledge in various industry sectors. Alongside you can also check some research papers, market reports, and forecasts that are talking about the “out of the box” developments in the market.
100 Church street, 8th floor,
Manhattan, New york, 10007
Phone No: +1 (646) 434-7969